Quick preview
A published comparison with retinol is a useful starting point, but it does not certify a raw-material grade or guarantee performance in another formula. This article reviews the study design and its limits, then translates ingredient selection into an incoming-quality review and a controlled stability plan. It compares the roles of bakuchiol, THD ascorbate and squalane, and closes with a source-by-source summary of the numerical evidence and the decisions that still require your own tests.
Requirements: define the product and the strength of evidence
Start with the actual development brief
Describe the product format, target user, intended market, proposed claims, manufacturing process and final packaging before choosing a bakuchiol grade. An anhydrous facial oil, an emulsion and a fragranced complex formula are different development systems. Ask what failure would matter commercially: visible color change, odor, active loss, separation, changed rheology, poor microbiological quality or a packaging interaction. These endpoints require different observations and sometimes different analytical methods. A development brief turns a general ingredient story into a set of questions your laboratory can actually answer.
Read the published comparison at its real scale
Dhaliwal and colleagues reported a randomized, double-blind study involving 44 patients over 12 weeks. The comparison was 0.5% bakuchiol cream applied twice daily against 0.5% retinol cream applied daily. The abstract reports improvement in wrinkle surface area and hyperpigmentation in both groups, with no statistically significant between-group difference, and more scaling and stinging reported by retinol users. These are outcomes of the studied creams and regimens. The publication is a clinical comparison, not a stability study of bulk RAWESS bakuchiol. [1]
Keep the limitations attached to the finding
The application schedules differed, so matching the percentage does not mean the groups received identical daily application exposure. A study of 44 patients over 12 weeks cannot by itself establish universal equivalence, long-term tolerability, suitability during pregnancy, or efficacy for unrelated conditions. A nonsignificant between-group result is not a guarantee that any two products are equivalent. Avoid presenting the study as a test of your finished formula, supplier grade or manufacturing process. Here the clinical details were checked against the published abstract; unreported effect sizes, dropout details or complete formulation information are not reconstructed or invented. [1]
Link the proposed claim to the right product
EU Regulation 655/2013 requires cosmetic claims to meet common criteria, including evidential support. Its annex warns against implying that a finished product has the same properties as an ingredient when it does not, and addresses extrapolation from ingredient properties to finished-product effects. Use published research to justify a development hypothesis, then assess whether the evidence supports the actual marketed claim, formulation and conditions of use. A supplier PDF, INCI listing or matching headline concentration does not perform that assessment. This is a claim-development distinction, not a promise of regulatory acceptance. [2]
Selection criteria: qualify the supplied grade and compare roles
Review identity, assay and relevant impurities
The RAWESS Bakuchiol page identifies the catalog material and lists an HPLC assay reference of at least 98.0%. Treat that as a published specification to confirm for the offered grade, not as a measurement of your delivery or a threshold proven to prevent discoloration. Ask for the current specification, lot COA, identity and assay methods, full supplied composition and relevant impurity information. Distinguish the defined ingredient from a broad botanical extract with a related plant name. If an isomer profile or another analytical property matters to the approval, clarify the method and acceptance basis before ordering.
Check the handling information before building a trial
Request current grade-specific storage, container, sampling and incorporation guidance. Record received condition, lot, opening date and any repacking. The site lists handling references for the catalog grade, but the actual shipment and current TDS must govern your laboratory brief. Ask which exposures are relevant to the proposed process, including heat, light, air and moisture, without assigning a universal temperature ceiling or working pH from a generic article. Minimize avoidable exposure during sampling, keep the closure practice consistent, and document the conditions rather than attributing every later change to ingredient purity.
Compare co-ingredients by function rather than label appeal
THD Ascorbate is a different oil-phase active ingredient with its own identity, assay and compatibility questions; it is not a drop-in substitute for bakuchiol or for water-soluble ascorbic acid. Olive Squalane is an emollient material and a possible component of an oil-system screening plan, not evidence that a particular bakuchiol mixture is stable or clinically effective. Review the complete oil blend, emulsifier and other ingredients as one system. The comparison below identifies development tasks, not a universal formulation recipe or a ranking of efficacy.
Separate appearance, concentration and product safety
A color change can be important, but it does not identify a chemical mechanism by itself. Conversely, a formula that looks unchanged may still require an assay or another relevant measurement. Select validated or otherwise justified methods and predefine meaningful acceptance criteria. For EU cosmetic safety assessment, Annex I of Regulation 1223/2009 includes physical and chemical characteristics, stability under reasonably foreseeable storage, microbiological quality and packaging-related information. Those categories explain why a simple visual check is insufficient; they do not prescribe the same protocol or shelf life for every formula. [3]
Bakuchiol, THD ascorbate and squalane: different roles, different checks
| Material | Development role | Main qualification question |
|---|---|---|
| Bakuchiol | Active ingredient for evaluation | Identity, assay, relevant impurities and behavior in the complete formula |
| THD Ascorbate | Different oil-phase active derivative | Derivative identity, oil-system compatibility and its own evidence |
| Olive Squalane | Emollient / oil-system component | Identity, origin documentation where required and blend compatibility |
Practical recommendation: design an interpretable stability investigation
Create a control and change one variable
Prepare a documented reference formula and a control or comparison suited to the question. To investigate a lot difference, hold formula, process and package constant; to investigate packaging, use the same prepared batch where appropriate and change the pack. Do not change active level, oil blend, emulsifier and storage condition together and then assign the result to one factor. Record equipment, mixing order, temperatures and times relevant to manufacture. Replicates, sampling intervals and test conditions should be justified by the project and laboratory rather than borrowed as universal numbers from a marketing article.
Track distinct endpoints throughout the protocol
At each planned observation, record appearance with a consistent description and, where useful, controlled photography or color measurement. Add odor, separation, viscosity or pH when applicable to the product format, plus analytical content or degradation-related measurements selected by the laboratory. Record sample handling so repeated opening does not create an unrecognized difference between test packs. An aqueous or water-containing system also needs appropriate microbiological and preservation evaluation. Treat an abnormal result as a reason to investigate rather than quietly removing it from the trend chart.
Use the final package and justify the shelf-life decision
Evaluate the intended container, closure and dispensing arrangement, including compatibility and exposure during foreseeable use. A pilot jar does not necessarily represent a commercial dropper or airless pack. Accelerated screening can help compare alternatives and identify weaknesses, but it does not automatically convert into a market shelf life. Commission guidance on cosmetic safety reports discusses the relationship between composition, stability information and packaging. Keep raw-material shelf life, opened-sample handling and finished-product shelf life as three separately justified decisions. [4]
Turn results into a purchasing and change-control brief
Approve the selected grade and formulation only after the required reviews resolve identity, analytical basis and performance in the intended system. Retain the reference sample and link results to ingredient lots, formula version and package. If a source, carrier, method or processing step changes, decide what must be repeated. Use the ingredient storage and stability guide and incorporation screening guide to prepare the work. Download the English product PDFs for shortlisting, then request the current lot COA, SDS and TDS rather than treating the catalog as release evidence.
Summary and next step
Use the clinical study to frame a hypothesis, the supplier documents to qualify the grade, and controlled trials to evaluate your formula and package. None of those evidence layers can substitute for the other two.
References and data summary
Numerical research data, catalog specifications and development recommendations are separated below. No customer survey or RAWESS clinical trial is claimed.
Read and checked: 1 November 2026
[1] Dhaliwal et al. — Bakuchiol versus retinol, BJD 2019;180:289–296. Source version / publication: 2019.
Dhaliwal et al., British Journal of Dermatology 2019;180:289–296, DOI 10.1111/bjd.16918, PMID 29947134. Abstract: 44 patients, 12 weeks; 0.5% bakuchiol twice daily vs 0.5% retinol daily. Study creams and schedules differ; the abstract does not establish universal equivalence, another product’s performance or bulk-ingredient stability.
[2] Regulation (EU) 655/2013 — common criteria for cosmetic claims. Source version / publication: 2013-07-10.
Annex: truthfulness and evidential support, including limits on attributing ingredient properties to the finished product. Framework for assessing claims, not regulatory approval of a bakuchiol formula.
[3] Regulation (EC) 1223/2009 — Article 10 and Annex I. Source version / publication: 2026-05-18.
Article 10 and Annex I: product safety assessment, stability, microbiology and packaging-related information. Requires product-specific assessment; no universal protocol or shelf-life number is supplied here.
[4] Commission Implementing Decision 2013/674/EU — Guidelines on Annex I. Source version / publication: 2013-11-25.
Annex: interpretation of stability and packaging information in the cosmetic safety report. Supports the assessment approach, not a prediction that one package or oil blend will pass.
Data and calculation notes
The ≥98.0% HPLC figure is the current RAWESS catalog specification for Bakuchiol, checked against the product page; it is not a delivered-lot result or an anti-discoloration threshold. Product comparisons identify technical roles only. The trial’s 44 participants, 12 weeks, concentrations and application frequencies are the only clinical quantities reported in this article.
Product evidence used in this article
- Bakuchiol — Catalog reference; request current lot documents.
- THD Ascorbate — Catalog reference; request current lot documents.
- Olive Squalane — Catalog reference; request current lot documents.
Related ingredient families
Bakuchiol is compared here as one member of the antioxidant and retinol-alternative group, and the same document discipline applies to the neighbouring families. The cosmetic active ingredients page sets out the assay and grade comparison for this group, Niacinamide USP gives a water-soluble worked example of an assay basis, and cosmetic peptides covers the materials where active mass per unit is the deciding number.